The use of everolimus in renal-transplant patients

International Journal of Nephrology and Renovascular Disease

Volumn 2, Issue , 2009, Pages 9-21

  Pascual, Julio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Calcineurin inhibitors; Chronic allograft nephropathy; Cyclosporine; Everolimus; Renal function; Renal transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

CELL PROLIFERATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDEMA; ENTERIC COATED TABLET; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PROPHYLAXIS; PROTEINURIA; REVIEW; SMOOTH MUSCLE FIBER; THERAPY DELAY; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

EID: 77953394981     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/ijnrd.s4191     Document Type: Review

References (66)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16:3015-3026.
3. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-565.
4. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
5. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005;80:244-252.
6. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5:2521-2530.
7. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4:626-635.
8. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996;14:483-510.
9. Viklicky O, Zou H, Muller V, et al. SDZ RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation. 2000;69:497-502.
10. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64:32-35.
11. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390-395.
12. Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc. 1999;31:1024-1025.
13. Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation. 2003;76:508-515.
14. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant. 2005;19:145-152.
15. Pascual J. Everolimus in clinical practice - renal transplantation. Nephrol Dial Transplant. 2006;21 Suppl 3:iii18-iii23.
16. Bennett WM. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol. 1995;43 Suppl 1:S3-S7.
17. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004;78:1332-1340.
18. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85:821-826.
19. Pascual J. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation. 2005;79:S76-S79.
20. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499-505.
21. EVEREST.ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ ct2/show/NCT00170885?term=CRAD001AIT02&rank=1. Accessed 05 January 2009.
22. Study A2309.ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00251004?term=crad001a2309&rank=1. Accessed 05 January 2009.
23. Study A2426.ClinicalTrials.gov. Available from: http://clinicaltrials. gov/ct2/show/NCT00369161?term=CRAD001A2426&rank=1. Accessed 05 January 2009.
24. HERAKLES Study.ClinicalTrials.gov. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00514514?term=crad001ade13&rank=1. Accessed 05 January 2009.
25. Study A2419.ClinicalTrials.gov. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00154284?term=crad001a2419&rank=1. Accessed 05 January 2009.
26. Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients (ASCERTAIN) study (A2413).ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00170846?term=crad001a2413&rank=1. Accessed 05 January 2009.
27. Holdaas H, Bentdal O, Pfeffer P, et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant. 2008;22:366-371.
28. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
29. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109:2168-2171.
30. Nashan B. The role of Certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc. 2001;33:3215-3220.
31. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant. 2007;21:149-158.
32. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008;40:1407-1410.
33. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant. 2007;22 Suppl 1:i11-i16.
34. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
35. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev. 2006;20:1-18.
36. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005;28:153-181.
37. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation. 2006;82:368-374.
38. Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int. 2007;20:27-36.
39. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney. Dis 2000;35:S97-S105.
40. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869-1875.
41. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando). 2008;22:125-130.
42. Muirhead N, House A, Hollomby DJ, Jevnikar AM. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc. 2003;35:2412-2414.
43. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369-391.
44. Andres V, Castro C, Campistol JM. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant. 2006;21 Suppl 3:iii14-iii17.
45. Magnani G, Vigano M, Maccherini M, et al. Everolimus- vs MMF-based immunosuppression: comparable lipid profiles at one year after cardiac transplantation [poster]. American Transplant Congress, Toronto, Canada, 30 May - 4 June. Am J Transplant. 2008;8(S2):347.
46. Kasiske BL, de MA, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8:1384-1392.
47. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002;42:222-228.
48. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant. 2003;3:562-569.
49. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol. 2005;46:481-486.
50. Waksman R, Pakala R, Burnett MS, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med. 2003;4:34-38.
51. Pascual J, Marcen R, Ortuno J. Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation. 2005;79:S80-S84.
52. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation. 2003;76:426-429.
53. Margreiter R, Vitko S, Whelchel J, et al. Post-operative tissue regeneration in renal transplantation: comparable outcome with everolimus or MMF. Transplantation Society XXII Annual Congress, August 10-14, Sydney, Australia. Transplantation. 2008;86(S2):188.
54. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation. 2001;72:162-164.
55. Moro JA, Almenar L, Martinez-Dolz L, et al. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc. 2008;40:3034-3036.
56. Champion L, Stern M, Israel-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med. 2006;144:505-509.
57. Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant. 2005;19:698-703.
58. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant. 2004;4:137-139.
59. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc. 2006;38:711-713.
60. De SP, Petruccelli S, Precisi A, et al. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient - not all proliferation signal inhibitors are the same: a case report. Transplant Proc. 2007;39:3500-3501.
61. Mycophenolate sodium vs Everolimus or Cyclosporine with Allograft Nephropathy as Outcome (MECANO) study. Netherlands Trial Register. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=567. Accessed 05 January 2009.
62. CALLISTO.ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ ct2/show/NCT00154297?term=CRAD001A2420&rank=2. Accessed 05 January 2009.
63. ZEUS.ClinicalTrials.gov. Available from:http://clinicaltrials.gov/ct2/ show/NCT00154310?term=CRAD001A2418&rank=1. Accessed 05 January 2009.
64. Steroid Or Cyclosporine Removal After Transplantation using EverolimuS (SOCRATES) study (A2421).ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00371826?term=crad001a2421&rank=1. Accessed 05 January 2009.
65. Study A2423.ClinicalTrials.gov. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00170807?term=crad001a2423&rank=1. Accessed 05 January 2009.
66. Kamar N, Jaafar A, Esposito L, et al. Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot study. Clin Nephrol. 2008;70:118-125.